Protalix BioTherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLX research report →
About the company
Protalix BioTherapeutics, Inc. , a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
- CEO
- Dror Bashan
- IPO
- 1998
- Employees
- 231
- HQ
- Hackensack, NJ, US
Price Chart
- Market Cap
- $186.93M
- P/E
- 12.01
- P/S
- 2.45
- P/B
- 2.76
- EV/EBITDA
- 6.88
- Div Yield
- 0.00%
- Gross Margin
- 69.97%
- Op Margin
- 25.91%
- Net Margin
- 20.07%
- ROE
- 28.10%
- ROIC
- 20.62%
- Revenue
- $52.74M · -1.23%
- Net Income
- $-6,604,000 · -325.24%
- EPS
- $-0.08 · -308.17%
- Op Income
- $-5,500,000
- FCF YoY
- -284.40%
- 52W High
- $3.19
- 52W Low
- $1.36
- 50D MA
- $2.08
- 200D MA
- $2.20
- Beta
- -0.00
- Avg Volume
- 731.55K
Get TickerSpark's AI analysis on PLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 24, 25 | Mamlok Gilad | other | 0 |
| Dec 19, 25 | Bashan Dror | buy | 56,000 |
| Nov 18, 25 | Bar-Shalev Amos | sell | 168 |
| Sep 3, 25 | Melincoff Gwen A | other | 15,000 |
| Sep 3, 25 | Forster Eliot | other | 15,000 |
| Sep 3, 25 | Forster Eliot | other | 7,500 |
| Sep 3, 25 | Melincoff Gwen A | other | 7,500 |
| Sep 3, 25 | Boudes Pol F | other | 15,000 |
| Sep 3, 25 | Boudes Pol F | other | 7,500 |
| Sep 3, 25 | Elze Christian | other | 15,000 |
Our PLX coverage
Recent articles, reports, and earnings notes.
No research on PLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLX report →Similar companies
Peers in the same neighborhood.